首页> 美国卫生研究院文献>Oncotarget >P-glycoprotein attenuates DNA repair activity in multidrug-resistant cells by acting through the Cbp-Csk-Src cascade
【2h】

P-glycoprotein attenuates DNA repair activity in multidrug-resistant cells by acting through the Cbp-Csk-Src cascade

机译:P-糖蛋白通过Cbp-Csk-Src级联反应减弱多药耐药细胞的DNA修复活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Recent studies have demonstrated that P-glycoprotein (P-gp) expression impairs DNA interstrand cross-linking agent-induced DNA repair efficiency in multidrug-resistant (MDR) cells. To date, the detailed molecular mechanisms underlying how P-gp interferes with Src activation and subsequent DNA repair activity remain unclear. In this study, we determined that the C-terminal Src kinase-binding protein (Cbp) signaling pathway involved in the negative control of Src activation is enhanced in MDR cells. We also demonstrated that cells that ectopically express P-gp exhibit reduced activation of DNA damage response regulators, such as ATM, Chk2, Braca1 and Nbs1 and hence attenuated DNA double-strand break repair capacity and become more susceptible than vector control cells to DNA interstrand cross-linking (ICL) agents. Moreover, we demonstrated that P-gp can not only interact with Cbp and Src but also enhance the formation of inhibitory C-terminal Src kinase (Csk)-Cbp complexes that reduce phosphorylation of the Src activation residue Y416 and increase phosphorylation of the Src negative regulatory residue Y527. Notably, suppression of Cbp expression in MDR cells restores cisplatin-induced Src activation, improves DNA repair capacity, and increases resistance to ICL agents. Ectopic expression of Cbp attenuates cisplatin-induced Src activation and increases the susceptibility of cells to ICL agents. Together, the current results indicate that P-gp inhibits DNA repair activity by modulating Src activation via Cbp-Csk-Src cascade. These results suggest that DNA ICL agents are likely to have therapeutic potential against MDR cells with P-gp-overexpression.
机译:最近的研究表明,P-糖蛋白(P-gp)的表达会损害多药耐药(MDR)细胞中DNA链间交联剂诱导的DNA修复效率。迄今为止,尚不清楚P-gp如何干扰Src激活和随后的DNA修复活性的潜在分子机制。在这项研究中,我们确定在MDR细胞中,参与Src激活负控制的C末端Src激酶结合蛋白(Cbp)信号通路得到增强。我们还证明,异位表达P-gp的细胞表现出减少的DNA损伤应答调节剂(例如ATM,Chk2,Braca1和Nbs1)的激活,因此减弱了DNA双链断裂修复能力,并且比矢量控制细胞更易受DNA链断裂的影响交联(ICL)代理。此外,我们证明P-gp不仅可以与Cbp和Src相互作用,而且可以增强抑制性C端Src激酶(Csk)-Cbp复合物的形成,从而降低Src激活残基Y416的磷酸化并增加Src阴性的磷酸化调控残基Y527。值得注意的是,抑制MDR细胞中的Cbp表达可恢复顺铂诱导的Src活化,提高DNA修复能力,并增加对ICL剂的抵抗力。 Cbp的异位表达减弱了顺铂诱导的Src活化,并增加了细胞对ICL药物的敏感性。总之,当前结果表明,P-gp通过Cbp-Csk-Src级联调节Src激活,从而抑制DNA修复活性。这些结果表明,DNA ICL试剂可能具有针对具有P-gp过表达的MDR细胞的治疗潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号